Document is current
Any future updates will be listed below
-
Authors
Patni, Nivedita https://orcid.org/0000-0002-5926-7784
Chard, Craig
Araújo-Vilar, David https://orcid.org/0000-0003-2852-7851
Phillips, Helen
Magee, David A.
Akinci, Baris
-
Funding
Funding for this research was provided by:
Amryt Pharma
- License Information
-
More Information
Article History
Received: 8 January 2024
Accepted: 5 June 2024
First Online: 11 July 2024
Declarations
:
: Ethics approval for this research was not applicable. Verbal informed consent was obtained from all individual participants included in the research prior to the interviews.
: Verbal informed consent was obtained from all individual participants to publish non-identifying information collected during the interview.
: NP has served as a consultant for Amryt Pharmaceuticals and Ionia Pharmaceuticals.CC is an employee of Lumanity Inc.DAV has received fees from Amryt Pharmaceuticals for scientific advice, travel, conference registration and research grants. DAV is the president of the executive board of the European Lipodystrophy Consortium.HP and DAM are employees of Chiesi Global Rare Diseases.BA run projects for and/or served as a consultant, board member, steering committee member, and/or speaker to Amryt Pharmaceuticals, Regeneron, Third Rock Ventures, Anylham, Astra Zeneca, Novo Nordisk, Boehringer Ingelheim, Sanofi, Bilim Ilic, ARIS, and Servier. BA is a member of the executive board of the European Lipodystrophy Consortium.
